MedCap : Presentation MedCap Q1 2023

Q1 Presentation 2023

We create value and contribute to improved quality of life in Life Science

2

Sales and EBITDA rolling 12 months by quarter

The Group's net sales LTM (MSEK)	The Group's EBITDA and EBITA (line) LTM (MSEK)
excluding one-time effects	excluding one-time effects

1. 320

1. 220

1 120

1 020

920

820

720

620

							300
							1 229							239	257
							250					216	228
						1 111
										203
									187
					1 046		200
						166	174
				1 007							203
			956									187
		916				150					167	178
	885								160
								145
858								133
						100	127
							50
							0	21Q2	21Q3	21Q4	22Q1	22Q2	22Q3	22Q4	23Q1
21Q2	21Q3	21Q4	22Q1	22Q2	22Q3	22Q4	23Q1

3

MedCap | An active investor in Life Science companies

First Quarter 2023

Sales by Business Area

Specialty
Pharma
35%	1 229

MSEK

MedTech

65%

Sales by Product Category

Oth Food 2%

(Nutrition...)

15%	Pharma
	32%

Medical

Devices

15%

Assistive

Technology

36%

Sales by Market

RoW 3%

Europe

25%

Nordic

23%

Sweden

49%

4

MedCap Platforms

Assistive Technology		Diagnostic ECG		Probiotics, Nutrition		Components for		Pharma & CDMO
				CDMO and Packaging		medical imaging

Position	Simplifying life for people	Digitalizing work-flow with easy	Partner for contract	Partner for carbon fiber
	with special needs	to use ECG	manufacturing	engineering & manufact'ng
	•	Prevalence of e.g. Autism,	•	Cardio diagnostics	•	Wellness	•	Medical imaging
Drivers		ADHD, Dementia	•	Hospital digitalization	•	Fitness	•	Mammography
•	Independence, accessibility,		and integration

and mobility

• Aging population

Markets	• Nordics, Netherlands, UK,	• Nordics, Germany, Europe	• Nordics	• Europe, USA
	Global Exports	Exports
		MedTech		MedTech		MedTech		MedTech

Developing and marketing specialty pharma in Nordics

• Pharmaceutical demand in e.g. Infection; Acute care; ADHD; Substance abuse
• Pharmaceutical shortages
• Nordics,
  Outlicensing in Europe

Specialty Pharma

5